Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine

New England Journal of Medicine

Volumn 332, Issue 23, 1995, Pages 1553-1559

  Epstein, Franklin H ^a   Lefkovits, Jeffrey ^b   Plow, Edward F ^b   Topol, Eric J ^b  

^a Cleveland Clinic Foundation ^*

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLCYSTEINYLASPARAGINYL 5,5 DIMETHYLTHIOPROLYL 4 AMINOMETHYLPHENYLALANYLGLYCYLASPARTYLCYSTEINE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; LAMIFIBAN; MEMBRANE PROTEIN; TIROFIBAN; UNCLASSIFIED DRUG; XEMILOFIBAN;

CARDIOVASCULAR DISEASE; CORONARY ARTERY DILATATION; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; UNSTABLE ANGINA PECTORIS;

CARDIOVASCULAR DISEASES; HUMAN; PLATELET AGGREGATION INHIBITORS; PLATELET MEMBRANE GLYCOPROTEINS;

EID: 0029062761     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199506083322306     Document Type: Review

References (81)

1. Hynes RO Integrins: a family of cell surface receptors. Cell 1987; 48: 549-554
2. Smyth SS, Joneckis CC, Parise LV Regulation of vascular integrins. Blood 1993; 81: 2827-2843 [Erratum, Blood 1994;83:2013.]
3. Kroll MH, Harris TS, Moake JL, Handin RI, Shafer AI von Willebrand factor binding to platelet GpIb initiates signals for platelet activation. J Clin Invest 1991; 88: 1568-1573
4. Fitzgerald LA, Phillips DR. Platelet membrane glycoproteins. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and thrombosis: basic principles and clinical practice. 2nd ed. Philadelphia: J.B. Lippincott, 1987:572-93.
5. Hantgan RR, Hindriks G, Taylor RG, Sixma JJ, de Groot PG Glycoprotein Ib, von Willebrand factor, and glycoprotein IIb:IIIa are all involved in platelet adhesion to fibrin in flowing whole blood. Blood 1990; 76: 345-353
6. Lages B, Weiss HJ Evidence for a role of glycoprotein IIb-IIIa, distinct from its ability to support aggregation, in platelet activation by ionophores in the presence of extracellular divalent cations. Blood 1994; 83: 2549-2559
7. Saelman EU, Nieuwenhuis HK, Hese KM, Platelet adhesion to collagen types I through VIII under conditions of stasis and flow is mediated by GPIa/IIa (α2β1-integrin). Blood 1994; 83: 1244-1250
8. Kunicki TJ, Nugent DJ, Staats SJ, Orchekowski RP, Wayner EA, Carter WG The human fibroblast class II extracellular matrix receptor mediates platelet adhesion to collagen and is identical to the platelet glycoprotein Ia-IIa complex. J Biol Chem 1988; 263: 4516-4519
9. Tandon NN, Kralisz U, Jamieson GA Identification of glycoprotein IV (CD36) as a primary receptor for platelet-collagen adhesion. J Biol Chem 1989; 264: 7576-7583
10. Asch AS, Barnwell J, Silverstein RL, Nachman RL Isolation of the thrombospondin membrane receptor. J Clin Invest 1987; 79: 1054-1061
11. Ginsberg MH, Xiaoping D, O'Toole TE, Loftus JC, Plow EF Platelet integrins. Thromb Haemost 1993; 70: 87-93
12. Coller BS. Platelets in cardiovascular thrombosis and thrombolysis. In: Fozzard HA, Haber E, Jennings RB, Katz AM, Morgan HE, eds. The heart and cardiovascular system: scientific foundations. 2nd ed. Vol. 1. New York: Raven Press, 1991:219-73.
13. Berridge MJ Inositol triphosphate and diacylglycerol: two interacting second messengers. Annu Rev Biochem 1987; 56: 159-193
14. Fuster V, Jang IK. Role of platelet-inhibitor agents in coronary artery disease. In: Topol EJ, ed. Textbook of interventional cardiology. 2nd ed. Vol. 1. Philadelphia: W.B. Saunders, 1994:3-22.
15. Plow EF, D'Souza SE, Ginsberg MH Ligand binding to GPIIb-IIIa: a status report. Semin Thromb Hemost 1992; 18: 324-332
16. Poncz M, Eisman R, Heidenreich R, Structure of the platelet membrane glycoprotein IIb: homology to the alpha subunits of the vitronectin and fibronectin membrane receptors. J Biol Chem 1987; 262: 8476-8482
17. Fitzgerald LA, Steiner B, Rall SC Jr, Lo SS, Phillips DR Protein sequence of endothelial glycoprotein IIIa derived from a cDNA clone: identity with platelet glycoprotein IIIa and similarity to “integrin.” J Biol Chem 1987; 262: 3936-3939
18. Phillips DR, Charo IF, Parise LV, Fitzgerald LA The platelet membrane glycoprotein IIb-IIIa complex. Blood 1988; 71: 831-843
19. Kunicki TJ, Pidard D, Rosa JP, Nurden AT The formation of Ca++-dependent complexes of platelet membrane glycoproteins IIb and IIIa in solution as determined by crossed immunoelectrophoresis. Blood 1981; 58: 268-278
20. Fujimura K, Phillips DR Calcium cation regulation of glycoprotein IIb-IIIa complex formation in platelet plasma membranes. J Biol Chem 1983; 258: 10247-10252
21. Nurden AT, Caen JP Abnormal platelet glycoprotein patterns in three cases of Glanzmann's thrombasthenia. Br J Haematol 1974; 28: 253-260
22. Phillips DR, Agin PP Platelet membrane defects in Glanzmann's thrombasthenia: evidence for decreased amounts of two major glycoproteins. J Clin Invest 1977; 60: 535-545
23. Rao AK, Holmsen H Congenital disorders of platelet function. Semin Hematol 1986; 23: 102-118
24. Bennett JS, Vilaire G Exposure of platelet-fibrinogen receptors by ADP and epinephrine. J Clin Invest 1979; 64: 1393-1401
25. Ginsberg MH, Forsyth J, Lightsey A, Chediak J, Plow EF Reduced surface expression and binding of fibronectin by thrombin-stimulated thrombasthenic platelets. J Clin Invest 1983; 71: 619-624
26. Ruggeri ZM, Bader R, de Marco L Glanzmann's thrombasthenia: deficient binding of von Willebrand factor to thrombin-stimulated platelets. Proc Natl Acad Sci U S A 1982; 79: 6038-6041
27. Gogstad GO, Brosstad F, Krutnes MB, Hagen I, Solum NO Fibrinogen-binding properties of the human platelet glycoprotein Iib-IIIa complex: a study using crossed-radioimmunoelectrophoresis. Blood 1982; 60: 663-671
28. Plow EF, Ginsberg MH GPIIb-IIIa as a prototypic adhesion receptor. Prog Hemost Thromb 1989; 9: 117-156
29. Parise LV, Phillips DR Reconstitution of the purified platelet fibrinogen receptor: fibrinogen binding properties of the glycoprotein IIb-IIIa complex. J Biol Chem 1985; 260: 10698-10707
30. Plow EF, Ginsberg MH Specific and saturable binding of plasma fibronectin to thrombin-stimulated platelets. J Biol Chem 1981; 256: 9477-9482
31. Plow EF, McEver RP, Coller BS, Woods VL Jr, Marguerie GA, Ginsberg MH Related binding mechanisms for fibrinogen, fibronectin, von Willebrand factor, and thrombospondin on thrombin-stimulated human platelets. Blood 1985; 66: 724-727
32. Plow EF, Srouji AH, Meyer D, Marguerie G, Ginsberg MH Evidence that three adhesive proteins interact with a common recognition site on activated platelets. J Biol Chem 1984; 259: 5388-5391
33. Weiss HJ, Hawiger J, Ruggeri ZM, Turitto VT, Thiagarajan P, Hoffmann T Fibrinogen-independent platelet adhesion and thrombus formation on subendothelium mediated by glycoprotein IIb-IIIa complex at high shear rate. J Clin Invest 1989; 83: 288-297
34. Pierschbacher MD, Ruoslahti E Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 1984; 309: 30-33
35. Ruoslahti E, Pierschbacher MD Arg-Gly-Asp: a versatile cell recognition signal. Cell 1986; 44: 517-518
36. D'Souza SE, Ginsberg MH, Plow EF Arginyl-glycyl-aspartic acid (RGD): a cell adhesion motif. Trends Biochem Sci 1991; 16: 246-250
37. Cheresh DA, Berliner SA, Vicente V, Ruggeri ZM Recognition of distinct adhesive sites on fibrinogen by related integrins on platelets and endothelial cells. Cell 1989; 58: 945-953
38. Farrell DH, Thiagarajan P, Chung DW, Davie EW Role of fibrinogen alpha and gamma chain sites in platelet aggregation. Proc Natl Acad Sci U S A 1992; 89: 10729-10732
39. Plow EF, Marguerie G, Ginsberg M Fibrinogen, fibrinogen receptors, and the peptides that inhibit these interactions. Biochem Pharmacol 1987; 36: 4035-4040
40. Yamada T, Matsushima M, Inaka K, Structural and functional analyses of the Arg-Gly-Asp sequence introduced into human lysozyme. J Biol Chem 1993; 268: 10588-10592
41. Kloczewiak M, Timmons S, Hawiger J Recognition site for the platelet receptor is present on the 15-residue carboxy-terminal fragment of the gamma chain of human fibrinogen and is not involved in the fibrin polymerization reaction. Thromb Res 1983; 29: 249-255
42. Kloczewiak M, Timmons S, Lukas TJ, Hawiger J Platelet receptor recognition site on human fibrinogen: synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the gamma chain. Biochemistry 1984; 23: 1767-1774
43. Weisel JW, Nagaswami C, Vilaire G, Bennett JS Examination of the platelet membrane glycoprotein IIb-IIIa complex and its interaction with fibrinogen and other ligands by electron microscopy. J Biol Chem 1992; 267: 16637-16643
44. Calvete JJ Clues for understanding the structure and function of a prototypic human integrin: the platelet glycoprotein IIb/IIIa complex. Thromb Haemost 1994; 72: 1-15
45. Ginsberg MH, Du X, Plow EF Inside-out integrin signalling. Curr Opin Cell Biol 1992; 4: 766-771
46. Fox JE The platelet cytoskeleton. Thromb Haemost 1993; 70: 884-893
47. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106 [Erratum, BMJ 1994;308:1540.]
48. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. II. Maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 1994; 308: 159-168
49. Coller BS, Peerschke EI, Scudder LE, Sullivan CA A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983; 72: 325-338
50. Huang TF, Holt JC, Kirby EP, Niewiarowski S Trigramin: primary structure and its inhibition of von Willebrand factor binding to glycoprotein IIb/IIIa complex on human platelets. Biochemistry 1989; 28: 661-666
51. Gan ZR, Gould RJ, Jacobs JW, Friedman PA, Polokoff MA Echistatin: a potent platelet aggregation inhibitor from the venom of the viper, Echis carinatus. J Biol Chem 1988; 263: 19827-19832
52. Dennis MS, Henzel WJ, Pitti RM, Platelet glycoprotein IIb/IIIa protein antagonists from snake venoms: evidence for a family of platelet-aggregation inhibitors. Proc Natl Acad Sci U S A 1990; 87: 2471-2475
53. Musial J, Niewiarowski S, Rucinski B, Inhibition of platelet adhesion to surfaces of extracorporeal circuits by disintegrins: RGD-containing peptides from viper venoms. Circulation 1990; 82: 261-273
54. Gould RJ, Polokoff MA, Friedman PA, Disintegrins: a family of integrin inhibitory proteins from viper venoms. Proc Soc Exp Biol Med 1990; 195: 168-171
55. Cox D, Aoki T, Seki J, Motoyama Y, Yoshida K The pharmacology of integrins. Med Res Rev 1994; 14: 195-228
56. Barker PL, Bullens S, Bunting S, Cyclic RGD peptide analogues as antiplatelet antithrombotics. J Med Chem 1992; 35: 2040-2048
57. Scarborough RM, Rose JW, Hsu MA, Barbourin: a GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem 1991; 266: 9359-9362
58. Coller BS, Folts JD, Scudder LE, Smith SR Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood 1986; 68: 783-786
59. Hanson SR, Pareti FI, Ruggeri ZM, Effects of monoclonal antibodies against the platelet glycoprotein IIb/IIIa complex on thrombosis and hemostasis in the baboon. J Clin Invest 1988; 81: 149-158
60. Gold HK, Coller BS, Yasuda T, Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation 1988; 77: 670-677
61. Yasuda T, Gold HK, Fallon JT, Monoclonal antibody against the platelet glycoprotein (GP) IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion and recombinant tissue-type plasminogen activator in dogs. J Clin Invest 1988; 81: 1284-1291
62. Collen D, Lu HR, Stassen JM, Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIIa inhibitors in animal models of platelet-mediated thrombosis. Thromb Haemost 1994; 71: 95-102
63. Rote WE, Davis JH, Mousa SA, Reilly TM, Lucchesi BR Antithrombotic effects of DMP 728, a platelet GPIIb/IIIa receptor antagonist, in a canine model of arterial thrombosis. J Cardiovasc Pharmacol 1994; 23: 681-689
64. Ellis SG, Tcheng JE, Navetta FI, Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. Coron Artery Dis 1993; 4: 167-175
65. Tcheng JE, Ellis SG, George BS, Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994; 90: 1757-1764
66. Anderson HV, Kirkeeide RL, Krishnaswami A, Cyclic flow variations after coronary angioplasty in humans: clinical and angiographic characteristics and elimination with 7E3 monoclonal antiplatelet antibody. J Am Coll Cardiol 1994; 23: 1031-1037
67. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961
68. Topol EJ, Califf RM, Weisman HF, Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994; 343: 881-886
69. Lefkovits J, Anderson K, Weisman H, Topol EJ. Mechanism of benefit of platelet IIb/IIIa receptor inhibition in high risk angioplasty in the EPIC trial: a hierarchical analysis. J Am Coll Cardiol 1995 (special issue):81A. abstract.
70. Matsuno H, Stassen JM, Vermylen J, Deckmyn H Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation 1994; 90: 2203-2206
71. Theroux P, Kouz S, Knudtson ML A randomized double-blind controlled trial with the non-peptidic platelet GP IIb/IIIa antagonist RO 44-9883 in unstable angina. Circulation 1994; 90: I-232 abstract.
72. Simoons ML, de Boer MJ, van den Brand MJ, Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994; 89: 596-603
73. Schulman SP, Goldschmit-Clermont PJ, Navetta FI, Integrelin in unstable angina: a double-blind randomized trial. Circulation 1993; 88: I-608 abstract.
74. Kleiman NS, Ohman EM, Califf RM, Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab following thrombolytic therapy: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 pilot study. J Am Coll Cardiol 1993; 22: 381-389
75. Ohman EM, Kleiman NS, Talley JD, Simultaneous platelet glycoprotein IIb/IIIa integrin blockade with accelerated tissue plasminogen activator in acute myocardial infarction. Circulation 1994; 90: I-564 abstract.
76. Aguirre F, Ferguson JJ, Califf RM Clinical predictors of bleeding complications in high risk angioplasty patients: results from the EPIC Study Group. Circulation 1993; 88: I-252 abstract.
77. Lincoff AM, Tcheng JE, Bass TA, et al. A multicenter, randomized, double-blind pilot trial of standard versus low dose weight-adjusted heparin in patients treated with the platelet GP IIb/IIIa receptor antibody c7E3 during percutaneous coronary revascularization. J Am Coll Cardiol 1995 (special issue):80A. abstract.
78. Plow EF, D'Souza SE, Ginsberg MH Consequences of the interaction of platelet membrane glycoprotein GPIIb-IIIa (αIIb β3) and its ligands. J Lab Clin Med 1992; 120: 198-204
79. Charo IF, Bekeart LS, Phillips DR Platelet glycoprotein IIb-IIIa-like proteins mediate endothelial cell attachment to adhesive proteins and the extracellular matrix. J Biol Chem 1987; 262: 9935-9938
80. Choi ET, Engel L, Callow AD, Inhibition of neointimal hyperplasia by blocking αvβ3 integrin with a small peptide antagonist GpenGRGDSPCA. J Vasc Surg 1994; 19: 125-134
81. Jang Y, Lincoff AM, Plow EF, Topol EJ Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol 1994; 24: 1591-1601